GEN Exclusives

More »

GEN News Highlights

More »
Nov 3, 2010

BMS and Simcere Partner to Carry out First-In-Man Trials of Oncology Candidate in China

  • Bristol-Myers Squibb (BMS) granted Chinese firm Simcere Pharmaceutical rights to develop and commercialize the preclinical-stage oncology compound BMS-817378 in its home country. While BMS retains rights to develop its small molecule MET/VEGFR-2 inhibitor in all other markets worldwide, the initial focus will be on the initiation of first-in-human studies in China. The two firms will work together to hammer out the development plan for BMS-817378, which will initially be conducted by Simcere.

    The U.S. drugs giant claims that marrying the strengths of a Chinese pharmaceutical firm and global pharma company represents a completely new approach to the development of its early-stage pipeline.

    “This approach allows the partnership to leverage our well-recognized clinical and regulatory capabilities and our access to the vast patient pool in China,” remarks Peng Wang, Ph.D., Simcare CEO. “


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Stopping Research Fraud

What is the best approach to curbing scientific misconduct and outright fraud?